Researchers at The Institute of Cancer Research, London, led work to develop a large panel of patient-derived mouse models of paediatric-type diffuse high-grade glioma (PDHGG) – a group of brain tumours with poor survival rates. Using magnetic resonance imaging (MRI), the research team demonstrated that these models reproduce key biological and radiological features of the human disease. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/advanced-imaging-reveals-how-ch

Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The findings provide a clearer understanding of how these tumors develop, explain why patients respond differently to immunotherapy, and are already helping guide more precise therapies. Read more: https://medicalxpress.com/news/2026-02-discovery-unique-brain-tumor-subtypes.html

The FDA granted rare pediatric disease designation to iopofosine-131 for treating relapsed or refractory pediatric high-grade glioma.   Read more: https://www.curetoday.com/view/fda-grants-rare-pediatric-designation-for-iopofosine-131-in-glioma-subset

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing...

A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most...

Part of a broader research study, the findings are helping to shape potential treatment approaches for patients with glioma based on the...

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts caution that...

Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than 18 months...